Biotechnology News and Research

RSS

Vertex receives positive opinion from European CHMP for approval of KALYDECO for cystic fibrosis

Vertex Pharmaceuticals Incorporated today announced that the European Committee for Medicinal Products for Human Use has issued a positive opinion recommending the approval of KALYDECO (ivacaftor) for people with cystic fibrosis (CF) ages 6 and older who have one of eight non-G551D gating mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

28 Jun 2014

Non-Hodgkin lymphoma subgroups found to have different survival rates

A Mayo Clinic-led group of researchers has discovered three subgroups of a single type of non-Hodgkin lymphoma that have markedly different survival rates. These subgroups could not be differentiated by routine pathology but only with the aid of novel genetic tests, which the research team recommends giving to all patients with ALK-negative anaplastic large-cell lymphoma (ALCL). Findings are published in the journal Blood.

27 Jun 2014

ALS is aggravated by over-activity of HDAC6 enzyme, shows study

Scientists at VIB and KU Leuven have demonstrated in fruit-flies that over-activity of the enzyme HDAC6 in the nerve ends exacerbates the symptoms of the neurodegenerative condition Amyotrophic Lateral Sclerosis (ALS / Lou Gehrig's Disease). Inhibition of this enzyme could offer a protective effect against ALS.

27 Jun 2014

Scientists map molecular olfactory signatures of individual foodstuff

How are we able to recognize foodstuffs like strawberries, coffee, barbecued meat or boiled potatoes by smell alone? Foodstuffs contain more than 10,000 different volatile substances.

27 Jun 2014

Study proposes moving open enrollment season

Researchers suggest consumers are not willing to spend money on insurance in the busy fall season as they plan for the holidays so sign-ups in the spring after tax returns are received might be better. Also, a look at consumers' reluctance to shop for insurance

27 Jun 2014

Auxilium Pharmaceuticals plans to merge with QLT

Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, and QLT Inc., a Canadian-based biotechnology company focused on developing innovative orphan ophthalmology products, today announced that they have entered into a definitive agreement under which Auxilium plans to merge with QLT.

26 Jun 2014

CareCloud receives $25.5 million debt financing commitment from HTGC

CareCloud, the leading provider of cloud-based practice management, electronic health records, and medical billing software and services, today announced that it has received a $25.5 million debt financing commitment from Hercules Technology Growth Capital, Inc., the leading specialty finance company focused on providing senior secured loans to venture capital-backed companies in technology-related markets, including technology, biotechnology, life science, and energy & renewable technology industries, at all stages of development.

26 Jun 2014

Preventing antibiotic side effects: an interview with Florence Séjourné, CEO, Da Volterra

Like all drugs, antibiotics can have side-effects when administered to people. The most common (and often benign) side effect people experience when taking antibiotics is “associated diarrhea”. This illustrates the fact that antibiotics have an impact on the intestine!

25 Jun 2014

Study explores how visual skills of cricket players change with age

Scientists at Royal Holloway, University of London, will investigate how cricket players' ability to play shots changes over the course of a lifetime in a new study into eye movements and skill learning.

25 Jun 2014

Cardium reports positive results from Generx Ad5FGF-4 Phase 3 study for treatment of myocardial ischemia

Taxus Cardium Pharmaceuticals Group Inc. will report today at the Biotechnology Industry Organization’s 2014 BIO International Convention on a pre-specified interim analysis from its international ASPIRE Phase 3 registration clinical study of Generx Ad5FGF-4, Cardium Therapeutics’ angiogenic gene therapy product candidate for patients with myocardial ischemia due to coronary artery disease.

25 Jun 2014

Microparticles in crab, shrimp and lobster shells may help prevent inflammatory bowel disease

Yoshimi Shibata, Ph.D., professor of biomedical science in the Charles E. Schmidt College of Medicine at Florida Atlantic University, has received a $380,552 grant from the National Institute of Complementary and Alternative Medicine of the National Institutes of Health to further investigate how microparticles called "chitin" found in crab, shrimp and lobster shells have anti-inflammatory mechanisms that could lead to the development of novel preventive and therapeutic strategies for individuals who suffer from inflammatory bowel disease (IBD) and others diseases.

24 Jun 2014

Researchers aim to accelerate development of brain mapping techniques

The California budget signed by Gov. Jerry Brown on June 20 creates a statewide research grants program called Cal-BRAIN, an initiative led by UC San Diego.

24 Jun 2014

Researchers develop GI microbiome modulators to treat prediabetes and diabetes

In adults with prediabetes, a new drug that alters microbial populations and their environment in the gastrointestinal (GI) tract improves glucose tolerance-the body's response to consuming carbohydrates- after four weeks of treatment and without a change in diet.

24 Jun 2014

Italian Medicines Agency grants marketing authorization to ILUVIEN for chronic DME treatment

pSivida Corp., a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the Italian Medicines Agency (Agenzia Italiana del Farmaco) has granted marketing authorization to ILUVIEN for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.

23 Jun 2014

Cincinnati Children’s, Alexion Pharmaceuticals establish ‘Rare Disease Innovation Fund’

Alexion Pharmaceuticals, Inc. and Cincinnati Children's Hospital Medical Center today announced the establishment of a collaboration and fund for the advancement of research in rare disease.

23 Jun 2014

USDM, DocuSign partner to help life science companies manage regulated business process

DocuSign, Inc. (DocuSign®) and USDM Life Sciences, a leading global regulatory consulting firm in the life sciences industry, today announced a new partnership to help organizations automate regulated business processes for dramatic ROI, increased security and compliance, and faster speed to market.

23 Jun 2014

Definiens closes €15M financing round to expand into digital tissue diagnostics

Definiens AG, which offers a unique approach to tissue diagnostics aimed at helping physicians improve treatment, said that it has closed a round of financing for € 15 million.

23 Jun 2014

New approach promises better drugs for diabetes and osteoporosis

By swapping replacement parts into the backbone of a synthetic hormone, UW-Madison graduate student Ross Cheloha and his mentor, Sam Gellman, along with collaborators at Harvard Medical School, have built a version of a parathyroid hormone that resists degradation in laboratory mice.

18 Jun 2014

3SBio signs exclusive license agreement with Selecta Biosciences for pegsiticase

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with Selecta Biosciences for pegsiticase (Uricase PEG-20), a pegylated recombinant uricase from candida utilis.

18 Jun 2014

Alexion announces that FDA grants ODD to Soliris for Myasthenia Gravis treatment

Alexion Pharmaceuticals (Nasdaq:ALXN) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to Soliris® (eculizumab) for the treatment of patients with Myasthenia Gravis (MG), a rare, debilitating neurologic disorder caused by uncontrolled complement activation.

17 Jun 2014

Biotechnology News and Research

Vertex receives positive opinion from European CHMP for approval of KALYDECO for cystic fibrosis

Non-Hodgkin lymphoma subgroups found to have different survival rates

ALS is aggravated by over-activity of HDAC6 enzyme, shows study

Scientists map molecular olfactory signatures of individual foodstuff

Study proposes moving open enrollment season

Auxilium Pharmaceuticals plans to merge with QLT

CareCloud receives $25.5 million debt financing commitment from HTGC

Preventing antibiotic side effects: an interview with Florence Séjourné, CEO, Da Volterra

Study explores how visual skills of cricket players change with age

Cardium reports positive results from Generx Ad5FGF-4 Phase 3 study for treatment of myocardial ischemia

Microparticles in crab, shrimp and lobster shells may help prevent inflammatory bowel disease

Researchers aim to accelerate development of brain mapping techniques

Researchers develop GI microbiome modulators to treat prediabetes and diabetes

Italian Medicines Agency grants marketing authorization to ILUVIEN for chronic DME treatment

Cincinnati Children’s, Alexion Pharmaceuticals establish ‘Rare Disease Innovation Fund’

USDM, DocuSign partner to help life science companies manage regulated business process

Definiens closes €15M financing round to expand into digital tissue diagnostics

New approach promises better drugs for diabetes and osteoporosis

3SBio signs exclusive license agreement with Selecta Biosciences for pegsiticase

Alexion announces that FDA grants ODD to Soliris for Myasthenia Gravis treatment

Event guide: 3rd IMPACCT Real World Evidence Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News